June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Intravitreal Half-lives of Aflibercept and Brolucizumab in Rabbit Measured Using In Vivo Fluorophotometry
Author Affiliations & Notes
  • Carl Romano
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Tara Liao
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Antonio Luz
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Ashique Rafique
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Krunal Patel
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Duo Sun
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Yang Liu
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Jingtai Cao
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York, United States
  • Footnotes
    Commercial Relationships   Carl Romano, Regeneron Pharmaceuticals, Inc (E); Tara Liao, Regeneron Pharmaceuticals, Inc (E); Antonio Luz, Regeneron Pharmaceuticals, Inc (E); Ashique Rafique, Regeneron Pharmaceuticals, Inc (E); Krunal Patel, Regeneron Pharmaceuticals, Inc (E); Duo Sun, Regeneron Pharmaceuticals, Inc (E); Yang Liu, Regeneron Pharmaceuticals, Inc (E); Jingtai Cao, Regeneron Pharmaceuticals, Inc (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4926. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Carl Romano, Tara Liao, Antonio Luz, Ashique Rafique, Krunal Patel, Duo Sun, Yang Liu, Jingtai Cao; Intravitreal Half-lives of Aflibercept and Brolucizumab in Rabbit Measured Using In Vivo Fluorophotometry. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4926.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the intravitreal half lives of aflibercept and brolucizumab using in vivo fluorophotometry of fluorescently labeled molecules in rabbits.

Methods : Aflibercept and brolucizumab were tagged with Alexa Fluor 488 (AF488) through amine conjugation. The binding kinetics of conjugated and un-conjugated aflibercept and brolucizumab were tested with serially diluted molecules passing over human VEGF165 coupled to a CM5 Biacore Chip. The kinetics parameters were evaluated by fitting the real time data using 1:1 binding model with mass transport limitation. Bilateral (intravitreal) IVT injections were made to 6 male New Zealand White (NZW) rabbits (6 eyes/3 rabbits /molecule). All eyes were examined for vitreous baseline fluorescence with OcuMetrics Fluorotron fluorophotometer (Mountain View, CA) before injection, and followed up for vitreous fluorescence intensity post injection at Day 2, 6, 10 and 14. General ocular examination included intraocular pressure (IOP), inflammation signs, corneal and conjunctival edema, hemorrhages, floaters in anterior chamber, pupil size and shape, cataract, and retinal detachment before and 10 minutes after IVT injection, and at each follow-up time point. Fluorescence intensity and position information were extracted and imported in GraphPad Prism for graphical display and analysis. The data were fitted to a first order, single compartment model.

Results : AF488 conjugation did not affect the affinity of either aflibercept or brolucizumab for human VEGF165. PK study of aflibercept and brolucizumab in NZW rabbit vitreous showed the half-lives were 4.7 (±0.7) and 3.0 (±0.1) days, respectively. There was no significant IOP change before and after IVT injection of either molecule. There were no clinically notable signs observed in general ocular examination.

Conclusions : The rabbit vitreal half-life of aflibercept measured conventionally in previous studies was 4.8 days, comparable to that measured here by in vivo fluorophotometry. Our study shows the half-life of brolucizumab is shorter than that of aflibercept in NZW rabbit vitreous, aflibercept persisting about 50% longer (4.7 days vs 3 days).

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×